To review recent literature on the topical treatment of allergic skin diseases to help clinicians make informed evidence-based decisions.
INTRODUCTION
Allergic skin diseases are common and include atopic dermatitis, allergic contact dermatitis, and urticaria [1] . Although these diseases may have differences in their pathophysiology, and therefore may differ in their specific recommended treatments, overall, therapies focus primarily on reduction of inflammation and symptomatic relief of pruritus.
According to recent guidelines for the treatment of atopic dermatitis, topical corticosteroids remain the primary foundation of topical treatment, with topical calcineurin inhibitors (TCIs) preferred for treatment of the face and intertriginous areas [2] . Regular, liberal use of emollients is also recommended, and can have a steroid-sparing effect [3, 4] . Recommended topical treatment of pruritus associated with atopic dermatitis also includes the use of topical corticosteroids, TCIs, and emollients [2] . Treatment considerations should include several factors, including age of the patient, severity of disease, and patient preference of therapy.
For allergic contact dermatitis (ACD) and urticaria, avoidance of the triggering allergen is key; however, identifying specific triggers is often difficult. The topical treatment ACD is similar to that of atopic dermatitis, with topical corticosteroids the mainstay of therapy, along with the use of emollients [5] . There is some evidence from studies in nickel contact dermatitis that TCIs may be of benefit as well [6] . For urticaria, both acute and chronic, oral antihistamines are first-line therapy with no topical therapy recommended [7] .
Familiarity with newer studies and treatment options help physicians make appropriate treatment recommendations. The objective of this study is to review recent research relevant to topical
RESULTS
Our literature search resulted in 23 publications on the topical treatment of atopic dermatitis, including 18 randomized clinical trials and five systematic reviews, and one publication, a randomized clinical trial, of topical treatment of allergic contact dermatitis. No publications were identified for the topical treatment of urticaria.
KEY POINTS
Literature on the topical treatment of atopic dermatitis focuses largely on the use of topical corticosteroids and TCIs.
Topical corticosteroids and TCIs are effective treatments for atopic dermatitis, with TCIs having the added benefit of improving skin barrier.
Barrier therapy continues to play an important role in the treatment of atopic dermatitis.
Adjunct therapies including bleach baths, natural oils, and textiles can be beneficial in the treatment of atopic dermatitis.
PubMed search keywords 'atopic dermatitis, allergic contact dermatitis, and urticaria treatment' restricted to randomized clinical trials and systematic reviews of topical treatment 1 January 2013- 31 
Anti-inflammatory therapy
Our literature search identified 10 publications regarding topical anti-inflammatory therapy of atopic dermatitis (Tables 1 and 2) . Two studies compared a topical corticosteroid with a TCI. In a study by Danby et al. [8] , topical betamethasone valerate and topical tacrolimus were compared in regard to their effects on skin barrier in patients with quiescent atopic dermatitis (history of atopic dermatitis with no symptoms for 6 months). Betamethasone valerate reduced both skin barrier function, bringing the transepidermal water loss (TEWL) closer to levels seen in patients with active atopic dermatitis, and skin hydration, whereas tacrolimus preserved skin barrier function and improved skin hydration. Tacrolimus also reduced skin pH and trypsin-like protease activity greater than treatment with the topical corticosteroid. Overall in patients with quiescent atopic dermatitis, betamethasone negatively impacted the condition of the skin, whereas tacrolimus improved the condition of the skin barrier. In patients with active atopic dermatitis, topical tacrolimus decreased TEWL and increased the lipid lamellae in the stratum corneum greater than mometasone furoate [9] . The TCI also doubled skin hydration, whereas the topical corticosteroid had no effect. Both were effective in terms of improvement in the SCORing Atopic Dermatitis (SCORAD). Another study by Jensen et al. [10] reported similar findings with the TCI topical pimecrolimus, which was superior at improving stratum corneum hydration and increasing the number of lamellar bodies when compared with the corticosteroid triamcinolone acetonide in patients with atopic dermatitis. The topical corticosteroid group, however, had better clinical improvement, achieving greater reduction in the partial Eczema Area and Severity Index (EASI) scores, lesion size, and pruritus. In contrast to the study by Danby, the topical corticosteroid improved TEWL more than the TCI. Overall, from a systematic review of 17 studies, TCIs and mild/ moderate topical corticosteroids were reported to have comparable efficacy in treating atopic dermatitis and both were reported as being effective preventive treatment options [11] . Among the TCIs, tacrolimus 0.1% had greater efficacy than pimecrolimus 1% [11] .
Another aspect of atopic dermatitis to consider when evaluating treatment options is pruritus. Topical tacrolimus was well tolerated and effective in treating refractory perianal pruritus according to itch, EASI, and Dermatology Life Quality Index scores compared with placebo [12] . Both topical corticosteroids and TCIs alike have demonstrated utility in treating pruritus [13] . A review suggested that topical corticosteroids were the most effective agents at reducing atopic dermatitis-related pruritus, and that the higher the potency of the steroid, the less itch occurred [13] .
Vehicle choice can impact patient acceptance and adherence to treatment. Creams vs. ointments were compared in both children and adults, with patients preferring cream to ointment [14] . Pimecrolimus cream was reported preferred over tacrolimus ointment in terms of ease of use, quick absorption, lack of residue, and skin softness. Patients who used the pimecrolimus cream had better outcomes, according to the Investigator Global Assessment scale and reduction in affected body surface area.
Treatment regimens for administration of topical tacrolimus were also compared [15 & ]. After twice daily application of tacrolimus 0.1% for 4 weeks, once weekly application of tacrolimus during a 40-week maintenance phase generated results comparable to that of thrice weekly application according to EASI scores, time to first relapse, and number of disease exacerbations.
Lipoxin A4 is an eicosanoid with anti-inflammatory properties. One study [16] explored the effectiveness of lipoxin A4 (LXA4) in treating infantile eczema. Patients using 15R/S methyl-LXA4 twice daily for 10 days had improvement on the EASI, severity scale score, and the Infants' Dermatology Quality of Life Index in a cohort of 20 patients, with efficacy comparable to mometasone furoate. Rates of relapse were similar between the two groups, 40 days after treatment.
Barrier therapy
Barrier therapy, consisting of creams and ointments, was studied in the treatment of atopic dermatitis, with seven publications resulting from our literature search. Hoppe et al. [17] explored the effects of three types of moisturizers in patients with atopic dermatitis with regard to filaggrin (FLG) mutation status. Moisturizers with propylene glycol, glycerol, and urea all improved dryness score at 4 weeks, with greatest improvement in patients with FLGÀ/À genotype. TEWL decreased with treatment as well in all groups, but was most reduced in the glycerol treatment group. None of the moisturizing therapies had an impact on filaggrin (FLG) gene expression in patients with mutations. Twice daily therapy with None an emollient containing glycerol and paraffin for 28 days in young children with atopic dermatitis resulted in significant improvement in xerosis score, xerosis visual analog scale (VAS), and SCORAD compared with vehicle [18] . More patients in the emollient group (66%) than the vehicle group (46%) were considered responders. In patients that relapsed after therapy was stopped, restarting emollient led to improvement similar to initial treatment. The efficacy of a moisturizer containing 0.025% licochalcone A in a ceramide and linoleic lotion was compared with 1% hydrocortisone for the treatment of childhood atopic dermatitis [19] . Both treatments resulted in improvement on SCORAD; however, hydrocortisone was better at improving TEWL. Overall, moisturizers containing licochalcone can be beneficial in treating atopic dermatitis. In a separate study, a moisturizer containing ectoine had positive effects in adult atopic dermatitis patients and was well tolerated after 28 days of treatment.
Marini et al. [20] reported that this ectoine-containing moisturizer had efficacy comparable to that of a positive control, a nonsteroidal anti-inflammatory cream, with no significant differences in improvement in SCORAD, Investigator Global Assessment, and pruritus VAS scores.
Two publications discussed the use of ceramidecontaining moisturizers. A new moisturizer containing a ceramide precursor resulted in a significant improvement in TEWL, clinical dryness scores, and skin hydration after twice daily application for 27 days in adult patients with inactive atopic dermatitis [21] . Untreated control instead of a placebo was used in the study, limiting the ability to determine whether the improvement was a result of the pseudoceramide alone, the other active ingredients, or a combination of all the ingredients in the moisturizer. Recently developed moisturizers are now incorporating natural moisturizing factors, ceramides, and pseudoceramides, with some evidence of efficacy from a review of 33 studies on barrier therapy in atopic dermatitis [22 && ]. Findings from some of these studies were conflicting and inconsistent. Many of the trials had small sample sizes and did not assess all relevant parameters, making it difficult to draw conclusions regarding efficacy. The need for long-term studies was stressed.
Natural oils
Two publications in the literature explored the utility of natural oils in atopic dermatitis treatment. The first publication reported on two studies was as follows: olive oil compared with no treatment for 5 weeks and olive oil compared with sunflower seed oil for 4 weeks, both in patients with and without atopic dermatitis. Olive oil decreased stratum a systematic review and meta-analysis [28] Functional textiles 13 Certain textiles such as silk textile and silver-coated cotton are safe and associated with some improvement in AD; however, because of low-quality evidence, the strength of the actual recommendation for textile use is weak Timing of return office visit affects adherence to topical treatment in patients with AD: an analysis of five studies [30] Adherence factors in topical treatment 5
Factors that most influenced high adherence rates were shorter treatment periods and follow-up visits scheduled shortly after starting treatment. Longer length of study resulted in worse adherence Systematic reviews of topical treatment of atopic dermatitis. AD, atopic dermatitis; TC, topical corticosteroid; TCI, topical calcineurin inhibitor.
corneum thickness, with an increase in TEWL and caused mild erythema [23] . Patients with history of atopic dermatitis had a greater decrease in skin barrier function than patients without. Sunflower seed oil maintained skin barrier function and stratum corneum integrity and also increased skin hydration, with the greatest improvement in patients with history of atopic dermatitis. In another study [24] , both coconut oil and mineral oil resulted in improvement according to SCORAD and TEWL. Coconut oil and mineral oil decreased SCORAD scores by 68.2 and 38.1%, respectively. In addition, coconut oil improved TEWL from a baseline of 26.7 to 7.1 and mineral oil reduced TEWL from 24.1 to 13.6. Although both oils demonstrated improvement, coconut oil had greater improvement of TEWL and SCORAD scores. The findings of both studies suggest that not all natural oils are equally beneficial to the skin, and olive oil, in particular, may be damaging to both normal and atopic dermatitis skin.
Bleach baths
In a study by Wong et al. [25] , bleach baths were evaluated as an adjunctive treatment for atopic dermatitis; use of concurrent emollient and topical corticosteroid was allowed. Patients were instructed to soak in a bleach bath or placebo for 10 min twice daily for 2 months. These patients had greater improvement in EASI scores and BSA compared with placebo, and both groups reported reduced itch, with only the treatment group having a significant reduction in itch score at 2 months. Although the bleach baths resulted in a 53% reduction in Staphylococcus aureus colonization, there was no significant difference between treatment and placebo groups. A few patients in both groups experienced mild side-effects, including burning/stinging and dry skin.
Other topical therapies
Five-percent cis-urocanic acid (cis-UCA) emulsion cream was studied in adult patients with AD. In three separate studies, 5% cis-UCA tolerability was comparable with control vehicle [26] . cis-UCA applied twice daily for 28 days decreased TEWL and erythema significantly more than control vehicle at day 10 and day 28. Generalizability of these findings is limited because of a small sample size.
Textiles
Textile clothing has also been studied in atopic dermatitis management. Clothing made of cellulose fibers with silver ion-enriched seaweed improved SCORAD score, pruritus, and sleep quality; however, the improvement was not significantly different from the control group which wore 100% cotton clothing [27] . A systematic review of 13 publications concluded that the various textiles used in the literature were safe and some were effective; however, because of the low-quality evidence, the strength of the recommendation for textile use is weak [28] .
Factors associated with topical therapy
Parental education is an important aspect of atopic dermatitis management in children. A 2-day educational program for parents consisting of lectures, practical sessions, and group discussions was effective at decreasing atopic dermatitis severity at 6 months [29 & ]. Patients of parents that received the educational program regarding proper topical corticosteroid and emollient application showed improvement in SCORAD and pruritus scores, and parents had less anxiety over using topical corticosteroids compared with the group that did not receive intervention [29 & ].
Five studies that electronically measured patient adherence to topical corticosteroids for the treatment of atopic dermatitis were compared to determine factors that most influence compliance [30] . Higher adherence rates were associated with shorter treatment periods and shorter time between treatment initiation and follow-up visits.
Allergic contact dermatitis
Our literature search of topical treatment for ACD resulted in one publication (Table 3 ) [31] . This study [31] was specific to the treatment of vulvar dermatitis, including contact and allergic dermatitis. Patients were first treated with topical mometasone furoate 0.1% for 15 days or until they reached a VAS between 0 and 1, followed by treatment for 60 days with either a topical multicomponent cream containing anti-inflammatory and antiitching natural actives, including 18-beta glycyrrhetinic acid, levomenol, zanthalene, curcumin, tea tree oil, and lactic acid, or placebo. Although both groups maintained a VAS less than 1, significantly fewer patients in the treatment group needed to use mometasone during this treatment period compared with the placebo group: seven vs. 42 patients, respectively (a total of 23 applications compared with 682 applications).
CONCLUSION
Standard of care for atopic dermatitis continues to be the use of topical therapy, with corticosteroids remaining first-line treatment when conservative measures fail. The literature from our review continues to support the use of these therapies, with research focusing largely on topical corticosteroids and calcineurin inhibitors. Several studies [8, 10] compared these two therapies and reported that calcineurin inhibitors were as effective as steroids in treating atopic dermatitis, if not more in terms of improving the skin barrier. Although TCIs are especially useful for treatment of the face and intertriginous areas that are more prone to the adverse effects of topical corticosteroids, these studies indicate that TCIs may deserve a higher recommendation in the treatment of atopic dermatitis of the body. Although there is a Food and Drug Administration-issued black box warning on TCIs, several publications address the theoretical risk of malignancies and the lack of evidence behind these claims [32] [33] [34] . Because TCIs have an obvious benefit in the treatment of atopic dermatitis, physicians should be familiar with the facts concerning their safety in order to have educated discussions with patients. Similarly, patients need to be adequately educated on the safety of topical corticosteroids; this is especially important in that phobia of topical corticosteroids use has been cited as a barrier to treatment [35] [36] [37] . Topical corticosteroids vary in their potency and formulations, and generally there are several appropriate options to choose from depending on severity of disease, location being treated, and age of the patient. Some authors have suggested that some topical corticosteroids, such as mometasone furoate, have a better therapeutic index (fewer adverse effects with equivalence potency); however, there is no strong evidence to support this conclusion [38] .
Barrier therapy continues to be a fundamental aspect of atopic dermatitis treatment; creams, ointments, and moisturizers are all potential treatment options for atopic dermatitis. Overall the literature does not contain any substantial evidence to support the use of one type of barrier therapy over another. There is a trend in newly developed moisturizers to contain substances, such as ceramides, pseudoceramides, and natural moisturizing factors, with some evidence for efficacy; however, the research findings on these novel moisturizers are inconsistent [21,22 && ]. The literature on natural oils suggests that certain natural oils may be beneficial in the treatment of atopic dermatitis. Sunflower seed oil, coconut oil, and mineral oil were all reported to have positive effects, whereas olive oil had negative effects on normal and atopic dermatitis skin [23, 24] .
Textile use in atopic dermatitis may be of some benefit; however, because of an overall low quality of evidence, recommendations cannot be made [28] . Bleach baths as adjunct therapy were effective at improving atopic dermatitis and reducing S. aureus colonization, supporting the current recommendation to include bleach baths in the treatment regime for atopic dermatitis to help reduce microbial colonization and superinfections that can contribute to atopic dermatitis flares [2, 25] . Strategies to improve patient adherence were another recurring theme in the literature. Futamura et al. [29 & ] emphasized the importance of parental education on topical steroid application, whereas Shah et al. [30] provided insight on strategies to improve adherence, such as early follow-up visits and shorter treatment durations. Patient preferences play a role in adherence; patients are more likely to use medications they prefer and, therefore, have improved treatment outcomes. Patients preferred pimecrolimus cream to tacrolimus ointment and had better outcomes with the cream; however, these results differ from Torley et al.'s [11] systematic review on TCIs that reported tacrolimus was more effective than pimecrolimus [14] . Simpler regimens including less frequent dosing schedules can also improve adherence, and given that once weekly application of tacrolimus was comparable to three times weekly, simpler regimens should be considered when appropriate [15 & ]. Providing patients with options and addressing other factors that may negatively impact adherence include steroid phobias and the black box warning on TCIs may also be of benefit. Some populations of patients, including children and pregnant patients, deserve special consideration in the treatment of atopic dermatitis. Literature reviewed included infants and children and provided effective and safe treatment options [14, 16, 18, 19, 24, 25, 27] . Although pregnancy was not addressed, topical corticosteroids can be used safely in pregnancy [39] [40] [41] [42] . Evidence-based guidelines recommend using the least potent topical corticosteroid necessary to control disease, with mild/ moderate potency preferred over more potent topical corticosteroids [40] . TCIs are not recommended by the manufactures; however, their use for localized areas can be considered when topical corticosteroids or phototherapy are ineffective [41, 42] . Use of barrier therapy is especially important in children and pregnancy and should be encouraged.
Literature on the topical treatment of ACD was limited, with one publication on the treatment of vulvar dermatitis. This study suggests that a natural multicomponent cream, with anti-inflammatory and antiitch properties, may be beneficial as maintenance therapy after control of disease first with topical corticosteroid treatment.
Overall, the literature continues to provide strong recommendations for anti-inflammatory and barrier therapies for the treatment of atopic dermatitis, whereas the evidence supporting other adjunct therapies, such as textiles, natural oils, and bleach baths, remains limited. These adjunct therapies do provide the physician treatment options for patients seeking alternative therapies or who are fearful of potential risks of topical corticosteroids and TCIs. Ultimately, treatment regimens should be tailored to an individual's needs and preferences, keeping in mind evidence-based recommendations.
